New immune cell therapy targets Hard-to-Treat blood cancer

NCT ID NCT04555551

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new treatment called MCARH109 for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy uses specially modified immune cells to target a protein on the cancer cells. The main goal is to find the safest dose and see how well it works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge (Limited protocol activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited protocol activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (Limited protocol activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited protocol activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited protocol activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.